A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

The present invention relates a method for preparing a personalized tumor vaccine using magnetic induction hyperthermia (MIH) inactivation technique, falling within the field of medicine. In this method, a MIH nanoagent is used to generate localized heat within tumor cells upon exposure to an alternating magnetic field, triggering immunogenic cell death and inducing the emergence of neoantigens mutations in tumor cells. Depending on the specific requirements, two strategies can be utilized: one involves preparing a whole tumor cell vaccine containing multiple tumor antigens, while the other focuses on screening specific tumor neoantigens to create a targeted tumor neoantigen vaccine. Mouse model experiments demonstrated that the whole tumor cell vaccine prepared using this method effectively inhibited the growth of homologous tumors, with a tumor-free rate of 100% in the vaccination group. Using MIH for tumor cells inactivation offers several advantages, including the preservation of antigen integrity, enhanced antigen abundance, and an increase in the diversity and quantity of released endogenous adjuvants. All of these factors contribute to the creation of a highly immunogenic personalized tumor vaccine, which holds promise for inhibiting tumor growth, recurrence and metastasis.

The present invention relates a method for preparing a personalized tumor vaccine using magnetic induction hyperthermia (MIH) inactivation technique, falling within the field of medicine. In this method, a MIH nanoagent is used to generate localized heat within tumor cells upon exposure to an alternating magnetic field, triggering immunogenic cell death and inducing the emergence of neoantigens mutations in tumor cells. Depending on the specific requirements, two strategies can be utilized: one involves preparing a whole tumor cell vaccine containing multiple tumor antigens, while the other focuses on screening specific tumor neoantigens to create a targeted tumor neoantigen vaccine. Mouse model experiments demonstrated that the whole tumor cell vaccine prepared using this method effectively inhibited the growth of homologous tumors, with a tumor-free rate of 100% in the vaccination group. Using MIH for tumor cells inactivation offers several advantages, including the preservation of antigen integrity, enhanced antigen abundance, and an increase in the diversity and quantity of released endogenous adjuvants. All of these factors contribute to the creation of a highly immunogenic personalized tumor vaccine, which holds promise for inhibiting tumor growth, recurrence and metastasis.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

A pharmaceutical composition comprising biodegradable polymer microparticles comprising a somatostatin analogue or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition preferably provides a sustained release of the somatostatin analogue, or a pharmaceutically acceptable salt thereof, over 30 days or more.

A pharmaceutical composition comprising biodegradable polymer microparticles comprising a somatostatin analogue or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition preferably provides a sustained release of the somatostatin analogue, or a pharmaceutically acceptable salt thereof, over 30 days or more.

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.